Belite Bio’s (BLTE) “Buy” Rating Reiterated at Benchmark
Belite Bio (NASDAQ:BLTE – Get Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at Benchmark in a note issued to investors on Wednesday, MarketBeat reports. They currently have a $80.00 price objective on the stock. Benchmark’s target price points to a potential upside of 19.67% from the company’s current price. A […]
Belite Bio (NASDAQ:BLTE – Get Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at Benchmark in a note issued to investors on Wednesday, MarketBeat reports. They currently have a $80.00 price objective on the stock. Benchmark’s target price points to a potential upside of 19.67% from the company’s current price. A […]
